Lilly, Merus to develop T-cell redirecting bispecific antibodies

By The Science Advisory Board staff writers

January 19, 2021 -- Eli Lilly research and development group Loxo Oncology and oncology firm Merus have signed a research collaboration and exclusive license agreement with the goal of developing up to three CD3-engaging T-cell redirecting bispecific antibody therapies.

Under the deal, Merus will lead discovery and early-stage research efforts, while Loxo Oncology will handle additional research, development, and commercialization activities. Merus will receive $40 million in cash upfront, as well as an additional $20 million in equity investment by Lilly in Merus common shares, according to the vendors.

What's more, Merus is also eligible to receive up to $540 million in potential development and commercialization milestones per product, for a total of up to approximately $1.6 billion for three products. In addition, it will receive tiered royalties on product sales of any therapy commercialized from this collaboration, the companies said.

Lilly to acquire Prevail Therapeutics for $1B
Eli Lilly will acquire Prevail Therapeutics for a total consideration of up to $26.50 per share in cash, or an aggregate of approximately $1.04 billion,...
Lilly to provide U.S. with 650K more COVID-19 antibody doses
The U.S. government has purchased an additional 650,000 doses of Eli Lilly's neutralizing antibody, bamlanivimab, for $812.5 million.
FDA issues EUA for Lilly's JAK inhibitor plus remdesivir for COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug baricitinib, a janus kinase (JAK) inhibitor,...
Lilly, Precision BioSciences collaborate on genome editing
Eli Lilly and Precision BioSciences have entered a research collaboration and exclusive licensing agreement to utilize Precision's proprietary Arcus genome...
Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter